Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2005 2
2006 3
2007 3
2008 2
2009 1
2010 2
2011 2
2012 2
2014 2
2015 8
2016 4
2017 3
2018 5
2019 7
2020 5
Text availability
Article attribute
Article type
Publication date

Search Results

47 results
Results by year
Filters applied: . Clear all
Page 1
Thirty Years of Lactobacillus rhamnosus GG: A Review.
Capurso L. Capurso L. J Clin Gastroenterol. 2019 Mar;53 Suppl 1:S1-S41. doi: 10.1097/MCG.0000000000001170. J Clin Gastroenterol. 2019. PMID: 30741841 Review.
Lactobacillus rhamnosus GG (LGG) was the first strain belonging to the genus Lactobacillus to be patented in 1989 thanks to its ability to survive and to proliferate at gastric acid pH and in medium containing bile, and to adhere to enterocytes. ...The effect
Lactobacillus rhamnosus GG (LGG) was the first strain belonging to the genus Lactobacillus to be patented in 1989 thank
Lactobacillus rhamnosus GG prevents epithelial barrier dysfunction induced by interferon-gamma and fecal supernatants from irritable bowel syndrome patients in human intestinal enteroids and colonoids.
Han X, Lee A, Huang S, Gao J, Spence JR, Owyang C. Han X, et al. Gut Microbes. 2019;10(1):59-76. doi: 10.1080/19490976.2018.1479625. Epub 2018 Aug 6. Gut Microbes. 2019. PMID: 30040527 Free PMC article.
Disruption of intestinal barrier homeostasis is an important pathogenic factor in conditions such as irritable bowel syndrome (IBS). Lactobacillus rhamnosus GG (LGG) improves IBS symptoms through unclear mechanisms. Previous studies utilizing co …
Disruption of intestinal barrier homeostasis is an important pathogenic factor in conditions such as irritable bowel syndro
Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2 improve quality-of-life and IBS symptoms: a double-blind, randomised, placebo-controlled study.
Preston K, Krumian R, Hattner J, de Montigny D, Stewart M, Gaddam S. Preston K, et al. Benef Microbes. 2018 Sep 18;9(5):697-706. doi: 10.3920/BM2017.0105. Epub 2018 Jun 11. Benef Microbes. 2018. PMID: 29888656 Clinical Trial.
A combination of Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2 was compared to placebo for relief of symptoms of irritable bowel syndrome (IBS). ...
A combination of Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2 w …
Effect of Lactobacillus rhamnosus GG supernatant on serotonin transporter expression in rats with post-infectious irritable bowel syndrome.
Cao YN, Feng LJ, Liu YY, Jiang K, Zhang MJ, Gu YX, Wang BM, Gao J, Wang ZL, Wang YM. Cao YN, et al. World J Gastroenterol. 2018 Jan 21;24(3):338-350. doi: 10.3748/wjg.v24.i3.338. World J Gastroenterol. 2018. PMID: 29391756 Free PMC article.
AIM: To evaluate the effect of Lactobacillus rhamnosus GG supernatant (LGG-s) on the expression of serotonin transporter (SERT) in rats with post-infectious irritable bowel syndrome (PI-IBS). ...
AIM: To evaluate the effect of Lactobacillus rhamnosus GG supernatant (LGG-s) on the expression of serotonin transporter (SERT …
Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders.
Currò D, Ianiro G, Pecere S, Bibbò S, Cammarota G. Currò D, et al. Br J Pharmacol. 2017 Jun;174(11):1426-1449. doi: 10.1111/bph.13632. Epub 2016 Oct 25. Br J Pharmacol. 2017. PMID: 27696378 Free PMC article. Review.
Functional bowel disorders (FBD), mainly irritable bowel syndrome (IBS) and functional constipation (FC, also called chronic idiopathic constipation), are very common worldwide. ...Probiotics, in particular Saccharomyces boulardii and Lactobacilli (amo …
Functional bowel disorders (FBD), mainly irritable bowel syndrome (IBS) and functional constipation (FC, also ca …
Ehealth: low FODMAP diet vs Lactobacillus rhamnosus GG in irritable bowel syndrome.
Pedersen N, Andersen NN, Végh Z, Jensen L, Ankersen DV, Felding M, Simonsen MH, Burisch J, Munkholm P. Pedersen N, et al. World J Gastroenterol. 2014 Nov 21;20(43):16215-26. doi: 10.3748/wjg.v20.i43.16215. World J Gastroenterol. 2014. PMID: 25473176 Free PMC article. Clinical Trial.
AIM: To investigate the effects of a low fermentable, oligosaccharides, disaccharides, monosaccharides and polyols diet (LFD) and the probiotic Lactobacillus rhamnosus GG (LGG) in irritable bowel syndrome (IBS). ...
AIM: To investigate the effects of a low fermentable, oligosaccharides, disaccharides, monosaccharides and polyols diet (LFD) and the probio …
Probiotics in digestive diseases: focus on Lactobacillus GG.
Pace F, Pace M, Quartarone G. Pace F, et al. Minerva Gastroenterol Dietol. 2015 Dec;61(4):273-92. Minerva Gastroenterol Dietol. 2015. PMID: 26657927 Review.
The present review focuses on three main issues: 1) understanding why, at present, probiotics are so interesting for doctors and consumers; 2) reviewing the available data on probiotic use in digestive diseases, in particular irritable bowel syndrome (IBS), ( …
The present review focuses on three main issues: 1) understanding why, at present, probiotics are so interesting for doctors and consumers; …
A review of dose-responses of probiotics in human studies.
Ouwehand AC. Ouwehand AC. Benef Microbes. 2017 Apr 26;8(2):143-151. doi: 10.3920/BM2016.0140. Epub 2016 Dec 23. Benef Microbes. 2017. PMID: 28008787 Review.
For prophylaxis in colorectal cancer and relief of irritable bowel syndrome, no dose-response relation was determined. However, for blood pressure, a meta-analysis observed that higher doses (greater than 10(11) cfu) were more effective than lower doses. Meta …
For prophylaxis in colorectal cancer and relief of irritable bowel syndrome, no dose-response relation was determined. …
Probiotics in Functional Gastrointestinal Disorders.
Hojsak I. Hojsak I. Adv Exp Med Biol. 2019;1125:121-137. doi: 10.1007/5584_2018_321. Adv Exp Med Biol. 2019. PMID: 30578460 Review.
Infantile colic, constipation, functional abdominal pain (FAP), and irritable bowel syndrome (IBS) are the most common functional gastrointestinal disorders (FGID). ...Limited, yet encouraging, evidence exists for Lactobacillus rhamnosus GG (LGG …
Infantile colic, constipation, functional abdominal pain (FAP), and irritable bowel syndrome (IBS) are the most common …
Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.
Yoon JS, Sohn W, Lee OY, Lee SP, Lee KN, Jun DW, Lee HL, Yoon BC, Choi HS, Chung WS, Seo JG. Yoon JS, et al. J Gastroenterol Hepatol. 2014 Jan;29(1):52-9. doi: 10.1111/jgh.12322. J Gastroenterol Hepatol. 2014. PMID: 23829297 Clinical Trial.
BACKGROUND AND AIM: The efficacy of treatment with multispecies probiotics on irritable bowel syndrome (IBS) symptoms and the alterations of gut microbiota in patients who have taken probiotics were investigated. ...Patients were randomly assigned to two grou …
BACKGROUND AND AIM: The efficacy of treatment with multispecies probiotics on irritable bowel syndrome (IBS) symptoms a …
47 results
Jump to page
Feedback